Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of atezolizumab with platinum + etoposide in advanced LCNEC of the lung
2020-002683-31Phase 2Active
- Sponsor
- Technische Universität Dresden
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in large cell neuroendocrine carcinoma (LCNEC) and bronchial neuroendocrine tumor, sponsored by Technische Universität Dresden. Primary endpoint: overall survival. Started Mar 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
large cell neuroendocrine carcinoma (LCNEC)bronchial neuroendocrine tumor
Beyond the preview
Go deeper on 2020-002683-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002683-31.